JBM |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.5 TWD | +0.96% |
|
+8.81% | -.--% |
| Sales 2017 | 554M 17.13M 1.36B | Sales 2018 | 192M 5.95M 474M | Capitalization | 2.81B 86.8M 6.91B |
|---|---|---|---|---|---|
| Net income 2017 | 60M 1.86M 148M | Net income 2018 | -123M -3.8M -303M | EV / Sales 2017 | 5.87 x |
| Net Debt 2017 | 2.35M 72.65K 5.78M | Net Debt 2018 | 227M 7.01M 558M | EV / Sales 2018 | 15.8 x |
| P/E ratio 2017 |
53.5
x | P/E ratio 2018 |
-22.8
x | Employees | - |
| Yield 2017 |
0.07% | Yield 2018 |
-
| Free-Float | 82.63% |
More Fundamentals
* Assessed data
| 1 day | +0.96% |
| Managers | Title | Age | Since |
|---|---|---|---|
Chao Yuan Kuo
BRD | Director/Board Member | - | 23/06/11 |
Wei Chuan Liao
PRN | Corporate Officer/Principal | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wen Tien Huang
CHM | Chairman | - | 19/05/10 |
Man Hsia Chia
BRD | Director/Board Member | - | 19/05/10 |
Chao Yuan Kuo
BRD | Director/Board Member | - | 23/06/11 |
Joben Bio-Medical Co Ltd is a Taiwan-based company mainly engaged in the development and sale of new plant medicines, local Chinese herbal medicines, health foods and medical beauty products. The Company develops JBM-TC4 plant new drug, which has been patented, used to provide raw materials for cancer treatment drugs.
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 21.03M | |
| +26.28% | 48.09B | |
| -3.99% | 40.43B | |
| +45.32% | 40.62B | |
| -6.20% | 28.36B | |
| +6.36% | 24.89B | |
| -21.47% | 19.01B | |
| +27.58% | 12.09B | |
| -2.75% | 11.8B | |
| -2.02% | 11.88B |
- Stock Market
- Equities
- 4193 Stock
